The prevalence of chronic kidney disease (CKD) is on the rise globally, making clinical evaluations of prevention, diagnosis, and treatment to lessen renal function deterioration an important issue to alleviate the huge economic burden of medical expenditures on dialysis. Recent progress in knowledge on immune reactions such as vaccination or COVID-19 infection has changed the world. In addition, several novel biomarkers strongly implicate kidney injury as surrogate markers. Of course, big data epidemiologic analysis is always the best to recognize disease progression in the real-world setting so quickly.
In this research topic, we will focus on biomarkers, immune reactions, and epidemiologic analysis of kidney injury that will progress CKD. Pandemic viruses such as COVID-19, and its related vaccines were strongly related to long COVID presentation. From the Immune reaction aspect that may cause CKD progression. In addition, some unique and novel uremic toxin related biomarkers such as the receptor for advanced glycation end-products, P-cresol, Indoxyl Sulfate, and Acrolein reflect CKD progression were still entangled. Of course, factors affecting better or worse outcomes of CKD patients, including laboratory data (ferritin, iron saturation, parathyroid hormone, calcium, phosphate) and underlying disease (polycystic kidney disease, diabetes, glomerulonephropathy, hypertension) provided important real world data for epidemiological researches.
Basic studies at the cell or animal level, or clinical studies on CKD in human are welcome. Original research articles, reviews or case series focused on but not restricted to the following areas are encouraged,
● Influence of COVID-19 infection or vaccination on CKD patients
● Biomarkers such as the receptor for advanced glycation endproducts, P-cresol, Indoxyl Sulfate, and Acrolein, on disease progression in CKD patients
● Factors on slowing the progress of CKD: An epidemiology analysis
The prevalence of chronic kidney disease (CKD) is on the rise globally, making clinical evaluations of prevention, diagnosis, and treatment to lessen renal function deterioration an important issue to alleviate the huge economic burden of medical expenditures on dialysis. Recent progress in knowledge on immune reactions such as vaccination or COVID-19 infection has changed the world. In addition, several novel biomarkers strongly implicate kidney injury as surrogate markers. Of course, big data epidemiologic analysis is always the best to recognize disease progression in the real-world setting so quickly.
In this research topic, we will focus on biomarkers, immune reactions, and epidemiologic analysis of kidney injury that will progress CKD. Pandemic viruses such as COVID-19, and its related vaccines were strongly related to long COVID presentation. From the Immune reaction aspect that may cause CKD progression. In addition, some unique and novel uremic toxin related biomarkers such as the receptor for advanced glycation end-products, P-cresol, Indoxyl Sulfate, and Acrolein reflect CKD progression were still entangled. Of course, factors affecting better or worse outcomes of CKD patients, including laboratory data (ferritin, iron saturation, parathyroid hormone, calcium, phosphate) and underlying disease (polycystic kidney disease, diabetes, glomerulonephropathy, hypertension) provided important real world data for epidemiological researches.
Basic studies at the cell or animal level, or clinical studies on CKD in human are welcome. Original research articles, reviews or case series focused on but not restricted to the following areas are encouraged,
● Influence of COVID-19 infection or vaccination on CKD patients
● Biomarkers such as the receptor for advanced glycation endproducts, P-cresol, Indoxyl Sulfate, and Acrolein, on disease progression in CKD patients
● Factors on slowing the progress of CKD: An epidemiology analysis